However, the current status of clinical trials on anti-PD-1/PD-L1 for nasopharyngeal carcinoma remains unclear. Therefore, this study aims to provide a comprehensive analysis of the registered trials related to anti-PD-1/PD-L1 for nasopharyngeal carcinoma on ClinicalTrials.gov. M...
看到在clinical trials网站上,BMS登记了一项三期临床试验NCT06561386,Anti-PD-1抗体Nivolumab(O药)+Anti-LAG-3抗体Relatlimab联合化疗, 在PD-L1表达量为1-49%的非鳞状晚期非小细胞肺癌的一线治疗中,默沙东Anti-PD-1抗体Pembrolizumab(K药)联合化疗的,头对头比对三期临床试验,这一临床试验虽不敢说是标志性事件,但是...
70.Genmab与BioNtech合作开发的PD-L1 x 4-1BB双抗试图克服第一代4-1BB激动剂的缺陷。它通过阻断PD-1:PD-L1轴以及有条件地刺激4-1BB来重新激活抗肿瘤免疫反应。该双抗Fc没有免疫功能,它的PD-L1特异性臂对PD-L1检查点的阻断有持续活性,但4-1BB...
Our study suggests that the combination of a PD-1 antibody, an HDACi, and a VEGF antibody could be a promising treatment regimen for patients with MSS/pMMR advanced colorectal cancer. ClinicalTrials.gov registration: NCT04724239.This is a preview of subscription content, access via your ...
Anti-PD-1 clone NAT105 DIA-PD1说明书 Version:Page:2 1 of 3
The potential pitfalls and precautions, based on clinical experience from treating patients with cancer with PD-1/PD-L1 pathway inhibitors, are also described. Conclusions Anti-PD-1/PD-L1 therapy holds promise as adjunctive therapy for chronic infectious diseases such as tuberculosis and HIV, and ...
Clinical trials have explored multiple combinatorial regimens based on concrete evidence that combining targeted therapy and anti-PD-1 agents is feasible. Until now, studies have mainly focused on those therapies that target EGFR/HER, VEGFR, RTK, and pathways represented by PI3K/AKT/mTOR, WNT/β-...
更进一步,Roche和合作方Incyte决定关闭IDO抑制剂(Epacadostat)联合PD-L1抑制剂(Atezolizumab临床试验 ECHO-110的患者招募,官方给出的理由是招募进度缓慢。下图是clinicaltrials上显示的该临床项目状态: ECHO-110临床状态 在2017年召开的ASCO年会上, Incyte公布Epacadostat (IDO抑制剂)联合 Keytruda (pembrolizumab)治疗三...
Together, the clinical and translational data of this study indicate that metronomic VEX chemotherapy combined with PD-1 blockade can be a treatment option in patients with breast cancer. ClinicalTrials.gov Identifier: NCT04389073. This is a preview of subscription content, access via your ...
However, associations with clinical response were not investigated. We identified expanded TCRs present pre-treatment and tracked them post-treatment. We observed a trend for increased maintenance of expanded pre-existing clones in anti-PD-1 responders (p = 0.08) (Figure S8B), consistent with ...